Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-333 Dose-Ranging Study in OIC
NCT01983306Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of dolcanatide in opioid-induced constipation (OIC), sponsored by Valeant Pharmaceuticals. Started Nov 2013; status: completed.
02
Drugs
dolcanatide
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01983306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983306.